The aim of this study was to investigate the effect of nasal
calcitonin on chronic
back pain and disability attributed to
osteoporosis. The study design involved three groups of osteoporotic postmenopausal women suffering from chronic
back pain. Group I consisted of 40 women with vertebral fractures, group II of 30 women with degenerative disorders and group III of 40 patients with non specific chronic
back pain and without abnormality on plain X-rays.
Pain intensity was measured using a numerical rating scale (NRS) and disability due to
back pain was measured using the Oswestry disability questionnaire. The patients were randomly assigned to receive, for three months, either 200 IU intranasal
salmon calcitonin and 1,000 mg of oral
calcium daily (groups IA, IIA, IIIA) or 1,000 mg of oral
calcium daily (groups IB, IIB, IIIB). Repeated measures ANOVA showed that there were no significant time, group or interaction effects for
pain intensity and disability in any of the groups studied. Mean Oswestry and NRS scores were reduced during the follow-up period in the groups IA, IIIA, but the differences between the two time points were not statistically significant. Intranasal
calcitonin has no effect on chronic
back pain intensity and functional capacity of osteoporotic women regardless of the presence of fractures, degenerative disorders or chronic
back pain of non-specific etiology.